Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3.
Jung-Yun LeeYoo Young LeeJeong-Yeol ParkSeung-Hyuk ShimSe Ik KimTae Wook KongChul Kwon LimHyun Woong ChoDong Hoon SuhPublished in: Journal of gynecologic oncology (2023)
In the 2022 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Ovarian cancer: long-term follow-up data, new poly (ADP-ribose) polymerase (PARP) inhibitors, overall survival (OS) issues with PARP inhibitor monotherapy, hyperthermic intraperitoneal chemotherapy, immunotherapy, and antibody-drug conjugate; 2) Cervical cancer: surgery in early stage disease, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Corpus cancer: follow-up regimen, immune checkpoint inhibitor, WEE1 inhibitor, selective inhibitor of nuclear export. A special note was made on the withdrawal of PARP inhibitor from the market for heavily pretreated ovarian cancer patients based on the final OS results of ARIEL-4 and SOLO-3 due to concerns of increased risk of death.
Keyphrases
- early stage
- dna damage
- dna repair
- palliative care
- small cell lung cancer
- squamous cell carcinoma
- minimally invasive
- oxidative stress
- randomized controlled trial
- clinical trial
- stem cells
- open label
- cell therapy
- mesenchymal stem cells
- percutaneous coronary intervention
- study protocol
- big data
- deep learning
- childhood cancer
- double blind